Wang Ying, Chen Weili, Wang Junjun, Song Chao, Zhang Lei, Zhang Xin
High Magnetic Field Laboratory, CAS Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, China.
Science Island Branch of Graduate School, University of Science and Technology of China, Hefei, China.
J Magn Reson Imaging. 2025 Jan 9. doi: 10.1002/jmri.29704.
BACKGROUND: Pancreatic damage is a common digestive system disease with no specific drugs. Static magnetic field (SMF), the key component of magnetic resonance imaging (MRI), has demonstrated prominent effects in various disease models. PURPOSE: To study the effects of 0.1-9.4 T SMFs on pancreatic injury induced by alcohol, and acute pancreatitis (AP) induced by L-arginine (L-Arg). STUDY TYPE: Prospective, animal model. ANIMAL MODEL: Twelve healthy C57BL/6J male mice, 30 AP model male mice, and 30 alcohol-associated liver disease (AALD) model male mice. FIELD STRENGTH/SEQUENCE: 1.5-9.4 T SMFs for 12 hours and 0.1 T SMF for 72 hours. No imaging sequence was used. ASSESSMENT: Histological analysis on AALD mice pancreas was conducted. For L-Arg-induced AP mice, their body weight, food/water consumption, open field behavior, blood analysis, as well as histological analysis, inflammatory, oxidative stress of the pancreas were measured. In vitro cellular experiments were also conducted. STATISTICAL TESTS: Data are presented as means ± SD and analyzed using the two-tailed Student's t-test or one-way analysis of variance (ANOVA) test. P values <0.05 were considered statistically significant. RESULTS: 1.5-7 T SMFs significantly reduced alcohol-induced pancreatic damage, increasing the structurally intact acinar area from 51.5% to 78.3%, whereas the effect of 9.4 T SMF is not obvious. 0.1 T SMF can reduce the AP mice lethality, increase the structurally intact acinar area from 31.0% to 59.7%, associated with the reduced pancreatic inflammatory responses (78.1% reduction of F4/80 and 80.0% reduction of MPO), 20.0% decreased oxidative stress and 53.2% reduced pancreatic cell apoptosis. DATA CONCLUSION: High-field MRI may be safe for pancreatic-related diseases at the animal level. SMFs have a future potential to be developed as non-invasive and highly penetrating physical modalities for the treatment of pancreatic injury including AP. PLAIN LANGUAGE SUMMARY: This study aims to evaluate the safety and potential therapeutic effects of moderate- to high-intensity static magnetic fields (SMFs) on mice with pancreatic injury. Their findings revealed that SMFs between 1.5 and 7 Tesla (T) helped reduce alcohol-induced pancreatic damage, while a stronger 9.4 T showed no effect. Interestingly, for mice with L-arginine-induced acute pancreatitis, a weaker 0.1 T significantly increased the area of healthy acinar cells from 31.0% to 59.7%. These results not only suggest that MRI-related SMFs are safe for pancreatic diseases in animals, but also unravel the potential of SMFs as a future treatment option for pancreatic disorders. EVIDENCE LEVEL: N/A TECHNICAL EFFICACY: Stage 1.
背景:胰腺损伤是一种常见的消化系统疾病,目前尚无特效药物。静磁场(SMF)作为磁共振成像(MRI)的关键组成部分,已在多种疾病模型中显示出显著效果。 目的:研究0.1 - 9.4 T静磁场对酒精诱导的胰腺损伤以及L - 精氨酸(L - Arg)诱导的急性胰腺炎(AP)的影响。 研究类型:前瞻性动物模型研究。 动物模型:12只健康的C57BL/6J雄性小鼠、30只AP模型雄性小鼠和30只酒精性肝病(AALD)模型雄性小鼠。 场强/序列:1.5 - 9.4 T静磁场作用12小时,0.1 T静磁场作用72小时。未使用成像序列。 评估:对AALD小鼠胰腺进行组织学分析。对于L - Arg诱导的AP小鼠,测量其体重、食物/水摄入量、旷场行为、血液分析以及胰腺的组织学分析、炎症、氧化应激情况。还进行了体外细胞实验。 统计检验:数据以均值±标准差表示,采用双侧学生t检验或单因素方差分析(ANOVA)进行分析。P值<0.05被认为具有统计学意义。 结果:1.5 - 7 T静磁场显著减轻酒精诱导的胰腺损伤,使结构完整的腺泡面积从51.5%增加到78.3%,而9.4 T静磁场的效果不明显。0.1 T静磁场可降低AP小鼠的致死率,使结构完整的腺泡面积从31.0%增加到59.7%,同时胰腺炎症反应减轻(F4/80减少78.1%,MPO减少80.0%),氧化应激降低20.0%,胰腺细胞凋亡减少53.2%。 数据结论:在动物水平上,高场MRI对胰腺相关疾病可能是安全的。静磁场有潜力被开发为治疗包括AP在内的胰腺损伤的非侵入性、高穿透性物理治疗手段。 通俗易懂的总结:本研究旨在评估中高强度静磁场(SMF)对胰腺损伤小鼠的安全性和潜在治疗效果。他们的研究结果显示,1.5至7特斯拉(T)的静磁场有助于减轻酒精诱导的胰腺损伤,而更强的9.4 T则无效果。有趣的是,对于L - 精氨酸诱导的急性胰腺炎小鼠,较弱的0.1 T显著将健康腺泡细胞面积从31.0%增加到59.7%。这些结果不仅表明与MRI相关的静磁场对动物胰腺疾病是安全的,还揭示了静磁场作为未来胰腺疾病治疗选择的潜力。 证据水平:无 技术疗效:1级
J Magn Reson Imaging. 2025-1-9
Cochrane Database Syst Rev. 2021-4-19
Cochrane Database Syst Rev. 2017-12-22
Cochrane Database Syst Rev. 2020-10-19
Cochrane Database Syst Rev. 2018-2-6
Cochrane Database Syst Rev. 2022-5-20
Cochrane Database Syst Rev. 2017-4-21
Health Technol Assess. 2001
Cochrane Database Syst Rev. 2008-7-16